GT
NGM

Glenmede Trust’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Glenmede Trust’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-104
Closed -$1K – 2362
2020
Q3 		$1K Buy
104
+56
+117% +$1.02K ﹤0.01% 2415
2020
Q2 		$0 Buy
+48
New +$917 ﹤0.01% 2657

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Glenmede Trust's NGM Position: Q4 2020 in Review

Glenmede Trust sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2020, closing a stake of 104 shares — an estimated $1K sold.

Glenmede Trust first reported a position in NGM in Q2 2020 and held it in 2 quarters. The position peaked at $1K in Q3 2020. 88 funds tracked by Wall St. Rank hold NGM as of Q4 2020.

  • Glenmede Trust reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 104 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1K in Q3 2020.
  • 88 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.